Sitryx Therapeutics announces that Eli Lilly & Company has commenced a Phase 1 first-in-human study of SIT-011, a post-translational modification modulator program for chronic autoimmune and inflammatory diseases.
Burning Rock Biotech Limited announced that it has received written notification from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC dated December 29, 2023, indicating that for the last 30 consecutive business days, the closing bid price for the Company’s American depositary shares was below the minimum bid price of
Burning Rock Announces Receipt of Notification from NASDAQ – Jan 04, 2024 Read More »
Keros Therapeutics, Inc. announced the pricing of an underwritten public offering of 3,500,000 shares of common stock, at a public offering price of $40.00 per share.
Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock Read More »
SELLAS Life Sciences Group, Inc. announced that it intends to offer and sell shares of its common stock and warrants to purchase shares of common stock in a public offering.
SELLAS Life Sciences Announces Proposed Public Offering – Jan 04, 2024 Read More »
ANGLE plc is delighted to announce breakthrough results from DNA molecular analysis of cancer patient blood samples that provide a unique insight into the progression of each patient’s cancer and how this may be treated.
Angle PLC Announces Breakthrough Clinical Results Read More »
Longboard Pharmaceuticals, Inc. announced the pricing of an upsized underwritten public offering of 10,000,000 shares of its voting common stock at a price to the public of $21.00 per share.
Longboard Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock Read More »
Laekna announced that the company will present a novel therapeutical approach to treat liver fibrosis in the form of a poster at the NASH-TAG conference from January 4-6, 2024, in Park City, Utah.
Kuros Biosciences announced three advancements related to its MagnetOs portfolio of products: specifically positive results from the MAXA level 1 clinical trial comparing standalone MagnetOs to autograft in a real world patient population in the challenging posterolateral fusion procedure, and two 510 clearances from the U.S. Food and Drug Administration related to its MagnetOs family
Innate Pharma SA announced that the U.S. Food and Drug Administration has lifted the partial clinical hold placed on the lacutamab IND.
Innate Pharma SA announced that it has strengthened the Company’s leadership and corporate governance with the appointment of two new Executive Board members.
Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board Read More »
